Biodexa Pharmaceuticals Plc
BDRX
$7.77
-$0.57-6.84%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/10/2025
-
Benzinga
10/6/2025
-
Globe Newswire
10/4/2025
-
Ticker Report
9/26/2025
-
GuruFocus
9/26/2025
-
SeekingAlpha.com: All News
9/26/2025
-
TipRanks Financial Blog
9/26/2025
-
The Fly
9/22/2025
-
MarketBeat
9/21/2025
-
MarketBeat
9/13/2025
-
MarketBeat
9/12/2025
-
SeekingAlpha.com: All News
9/12/2025
-
TipRanks Financial Blog
9/12/2025
-
TipRanks Financial Blog
9/12/2025
-
The Fly
9/12/2025
-
Globe Newswire
9/10/2025
-
MarketBeat
9/8/2025
-
ACCESS Newswire
9/5/2025
-
MarketBeat
9/3/2025
-
MarketBeat
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?
9/3/2025
-
Zacks Investment Research
9/2/2025
-
MarketBeat
9/1/2025
-
MarketBeat
8/27/2025
-
MarketBeat
8/19/2025
-
MarketBeat
8/18/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, September 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Apr 6 and 10 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
44 29 2048 0180
Address
1 Caspian Point
Cardiff, CF10 4DQ
Cardiff, CF10 4DQ
Country
Year Founded
Business Description
Sector
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive...
more